On the public citation graph

Progress of SARS‐CoV‐2 Main protease peptide‐like inhibitors

https://doi.org/10.1111/cbdd.14425
0 signed · 50 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cbic.202000371openalex-snapshot
Peptidyl Acyloxymethyl Ketones as Activity‐Based Probes for the Main Protease of SARS‐CoV‐2**
inferredcites →https://doi.org/10.1002/cmdc.202000924openalex-snapshot
A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**
inferredcites →https://doi.org/10.1007/978-1-4939-2438-7_1openalex-snapshot
Coronaviruses: An Overview of Their Replication and Pathogenesis
inferredcites →https://doi.org/10.1007/s13238-021-00883-2openalex-snapshot
Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
inferredcites →https://doi.org/10.1016/j.bbrc.2005.02.061openalex-snapshot
The substrate specificity of SARS coronavirus 3C-like proteinase
inferredcites →https://doi.org/10.1016/j.bmcl.2013.08.112openalex-snapshot
Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding
inferredcites →https://doi.org/10.1016/j.bmcl.2020.127377openalex-snapshot
The SARS-CoV-2 main protease as drug target
inferredcites →https://doi.org/10.1016/j.ejmech.2021.113530openalex-snapshot
A cyclic peptide inhibitor of the SARS-CoV-2 main protease
inferredcites →https://doi.org/10.1016/j.jsb.2020.107575openalex-snapshot
SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3
inferredcites →https://doi.org/10.1016/j.tim.2016.09.001openalex-snapshot
Molecular Evolution of Human Coronavirus Genomes
inferredcites →https://doi.org/10.1016/j.vetmic.2019.108398openalex-snapshot
Characterization of amino acid substitutions in feline coronavirus 3C-like protease from a cat with feline infectious peritonitis treated with a protease inhibitor
inferredcites →https://doi.org/10.1021/acs.jmedchem.0c01063openalex-snapshot
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00509openalex-snapshot
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00616openalex-snapshot
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00665openalex-snapshot
3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents
inferredcites →https://doi.org/10.1021/acs.jmedchem.9b01828openalex-snapshot
α‑Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
inferredcites →https://doi.org/10.1021/acsinfecdis.0c00761openalex-snapshot
Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses
inferredcites →https://doi.org/10.1021/jacs.1c08060openalex-snapshot
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
inferredcites →https://doi.org/10.1021/jm050548mopenalex-snapshot
Design and Synthesis of Peptidomimetic Severe Acute Respiratory Syndrome Chymotrypsin-like Protease Inhibitors
inferredcites →https://doi.org/10.1038/s41422-020-0356-zopenalex-snapshot
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
inferredcites →https://doi.org/10.1038/s41467-020-18096-2openalex-snapshot
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
inferredcites →https://doi.org/10.1038/s41467-020-18463-zopenalex-snapshot
Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
inferredcites →https://doi.org/10.1038/s41467-021-26239-2openalex-snapshot
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
inferredcites →https://doi.org/10.1038/s41579-022-00841-7openalex-snapshot
SARS-CoV-2 variant biology: immune escape, transmission and fitness
inferredcites →https://doi.org/10.1038/s41579-023-00878-2openalex-snapshot
The evolution of SARS-CoV-2
inferredcites →https://doi.org/10.1038/s41586-020-2012-7openalex-snapshot
A pneumonia outbreak associated with a new coronavirus of probable bat origin
inferredcites →https://doi.org/10.1038/s41586-020-2223-yopenalex-snapshot
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
inferredcites →https://doi.org/10.1038/s41586-020-2286-9openalex-snapshot
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
inferredcites →https://doi.org/10.1039/d1md00247copenalex-snapshot
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors
inferredcites →https://doi.org/10.1073/pnas.0505577102openalex-snapshot
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry
inferredcites →https://doi.org/10.1074/jbc.m310875200openalex-snapshot
Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase
inferredcites →https://doi.org/10.1111/jnc.15736openalex-snapshot
SARS‐CoV ‐2, aging, and Post‐COVID ‐19 neurodegeneration
inferredcites →https://doi.org/10.1126/science.1085658openalex-snapshot
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
inferredcites →https://doi.org/10.1126/science.abb3405openalex-snapshot
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
inferredcites →https://doi.org/10.1126/science.abb4489openalex-snapshot
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
inferredcites →https://doi.org/10.1126/science.abf7945openalex-snapshot
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
inferredcites →https://doi.org/10.1126/science.abl4784openalex-snapshot
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
inferredcites →https://doi.org/10.1128/jvi.00998-13openalex-snapshot
Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Entry That Act by Three Distinct Mechanisms
inferredcites →https://doi.org/10.1177/1098612x17729626openalex-snapshot
Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
inferredcites →https://doi.org/10.1371/journal.pbio.0030324openalex-snapshot
Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
inferredcites →https://doi.org/10.3390/v13020174openalex-snapshot
Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4857328openalex-extracted
Identification of Adenosine Analogues as Nsp14 N7‑Methyltransferase Inhibitors for Treating Coronaviruses
inferred← citeshttps://doi.org/10.1002/ardp.202400812openalex-snapshot
Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3
inferred← citeshttps://doi.org/10.1002/cbdv.202403202openalex-snapshot
Amphibian‐Derived Peptides as Natural Inhibitors of SARS‐CoV‐2 Main Protease (M pro ): A Combined In Vitro and In Silico Approach
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c02009openalex-snapshot
Rational Design of Macrocyclic Noncovalent Inhibitors of SARS-CoV-2 M pro from a DNA-Encoded Chemical Library Screening Hit That Demonstrate Potent Inhibition against Pan-Coronavirus Homologues and Nirmatrelvir-Resistant Variants
inferred← citeshttps://doi.org/10.1021/acsmedchemlett.4c00474openalex-snapshot
Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in Particular Coronavirus Infections
inferred← citeshttps://doi.org/10.1021/acsmedchemlett.4c00553openalex-snapshot
Pyrrolidines as Main Protease Inhibitors for Treating Viral Infections, in Particular, Coronavirus Infections
inferred← citeshttps://doi.org/10.1021/mc-2024-vol59.ch13openalex-snapshot
PEPTIDIC OR NON-PEPTIDIC: EVALUATION OF SMALL-MOLECULE CHEMICAL MATTER IN TARGETING PROTEASES FOR ANTIVIRAL TREATMENT
inferred← citeshttps://doi.org/10.1080/14756366.2025.2604232openalex-snapshot
Insights into the complexity of SARS-CoV-2 M pro inhibition: Ebselen and its derivatives impair dimerisation of the enzyme
inferred← citeshttps://doi.org/10.3390/app15126544openalex-snapshot
In Silico Development of SARS-CoV-2 Non-Covalent Mpro Inhibitors: A Review
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.